Introduction

Palbociclib is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:

• ?an aromatase inhibitor as initial endocrine based therapy in postmenopausal women.
• fulvestrant in women with disease progression following endocrine therapy.

 Disclaimer:

The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.